Julie Diane Jolley, who serves as Executive Vice President of Home Health Operations at Enhabit, Inc. (NYSE: EHAB), sold a total of 5,586 shares of the company's common stock in two equal tranches on March 9 and March 10, 2026. The transactions were executed at $13.63 per share, producing proceeds of $76,137.
According to a Form 4 filed with the Securities and Exchange Commission, Jolley disposed of 2,793 shares on March 9 and an additional 2,793 shares on March 10. Following those sales, Jolley retains direct ownership of 137,130 shares of Enhabit.
The insider sales occurred while Enhabit shares were trading near a 52-week high - the stock's near-term peak is listed at $13.68. Over the prior 12 months, the stock produced a 59% return. Analysis from InvestingPro referenced in filings indicates that EHAB currently appears overvalued relative to its Fair Value estimate and is included among companies on the Most Overvalued list. The InvestingPro note also references 11 additional exclusive tips for EHAB and mentions Pro Research Reports that cover more than 1,400 US equities.
Separately, Enhabit Home Health & Hospice announced a definitive agreement to be acquired by Kinderhook Industries in an all-cash transaction valued at $13.80 per share. The offer values the company's total enterprise at approximately $1.1 billion. That proposed transaction has prompted several analyst firms to revisit their recommendations and price targets for the stock.
Specifically, TD Cowen, UBS, and Jefferies each moved to downgrade the stock and set a new price target of $13.80 per share. At the same time, Leerink Partners and Truist Securities raised their price targets to $13.80, reflecting the terms of the acquisition. Various analyst estimates place the transaction multiple at roughly 10 to 10.6 times estimated 2026 EBITDA.
These developments - the insider sale, the stock's recent strong one-year performance, and the announced acquisition with corresponding analyst reactions - represent material changes to the company's near-term profile. The deal terms and related analyst adjustments have altered market expectations as Enhabit moves forward with the proposed transaction.
Please note that the statements above are based on the Form 4 filing and the disclosures included in company and analyst communications referenced in public filings.